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Background: Hepatitis B virus infection is a very common cause of chronic liver disease
worldwide. It is estimated that 3% of Iranians are chronically infected with hepatitis B virus. Current
population-based studies on both rural and urban prevalence of hepatitis B virus infection in Iran
are sparse with results that do not always agree. We performed this study to find the prevalence of
hepatitis B surface antigen, anti-hepatitis B core antibody, and associated factors in the general
population of three provinces of Iran. 
Methods: We randomly selected 6,583 subjects from three provinces in Iran, namely Tehran,
Golestan, and Hormozgan. The subjects were aged between 18 and 65 years. Serum samples were
tested for hepatitis B surface antigen and anti-hepatitis B core antibody. Various risk factors were
recorded and multivariate analysis was performed.
Results: The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in
Iran was 2.6% and 16.4%, respectively. Predictors of hepatitis B surface antigen or anti-hepatitis B
core antibody in multivariate analysis included older age, not having high-school diploma, living in
a rural area, and liver disease in a family member. We did not find any significant differences
between males and females.
Conclusion: In spite of nationwide vaccination of newborns against hepatitis B virus since 
1992, hepatitis B virus infection remains a very common cause of chronic liver disease in Iran 
which should be dealt with for at least the next 30 – 50 years. 
Archives of Iranian Medicine, Volume 12, Number 3, 2009: 225 – 231. 
Keywords: Hepatitis B virus • Iran • prevalence 
Introduction 
 
epatitis B virus (HBV) infection is a 
serious global health problem with over 
two billion people infected worldwide H
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and 350 million suffering from chronic infection. It 
is the 10th leading cause of death worldwide and 
results in 500,000 to 1.2 million deaths per year 
due to cirrhosis and hepatocellular carcinoma 
(HCC).1 HBV infection is highly prevalent in the 
Western Pacific and South-East Asia where rates
as high as 35% have been reported.2 However, in 
the Middle-East, different rates are reported. Some
limited studies indicate that HBV infection is the 
cause of about 75% of cirrhosis and HCC in
Iran.3–5 But, nationwide population-based studies 
about the prevalence of HBV infection and its risk
factors are sparse in Iran.5 
Iran has been known as a medium-prevalence 
area. The first estimates of the prevalence of HBV
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HBV infection in Iran 
infection in Iran, about 30 years ago, indicated that 
approximately 35% of Iranians were exposed to 
HBV and 3% were chronic carriers.6,7 These
studies, carried out on blood donors during the 
early years of the foundation of the Blood 
Transfusion Organization in Iran, may have been a 
good estimate of chronic HBV infection but cannot 
be generally assumed to be representative of the
general population. In another study performed 
during 1990 – 1991 on 39,841 subjects, randomly 
selected from all the country, a mean prevalence of 
1.7% was observed for hepatitis B surface antigen
(HBsAg) positivity.8 This study included subjects 
as young as two years old.  
During the last 30 years, many researchers have
studied the prevalence of HBV infection in special 
populations in Iran. These populations include
subjects with hemophilia, major thalassemia,
sexually transmitted diseases, Behcet’s disease,
patients on chronic hemodialysis, pregnant women, 
prisoners, drug abusers, truck drivers, etc.9–16 
Vaccination against HBV has been routinely 
performed for newborns and high-risk groups since 
1992 and adulthood vaccination has been done 
since 2007. It is believed to change the
epidemiologic pattern of HBV infection especially 
in children and adolescents. The effects are now
discernible in younger Iranians.17 Continuous 
surveillance of this infection and its risk factors is 
essential for better health planning. 
New population-based studies are rather sparse.
From current literature, it is obvious that the 
prevalence is significantly varied in different 
provinces of Iran. Nevertheless, serial studies on 
the prevalence of HBV infection in various
provinces are essential for health planning and 
monitoring. 
In this study, we assessed the prevalence and 
determinants of exposure to HBV infection in three 
provinces of Iran. 
Materials and Methods 
Design and settings 
 This cross-sectional study was performed during 
 
 
   
    
   
    
   
Table 1. Census information on Iran and the three provinces studied.*
Area (km2) Population Percent urban Percent male Literacy
Iran
Tehran
Hormozgan 
Golestan
 1,648,195
18,814
70,697
20,367
70,495,782
13,422,366
1,403,674
1,617,087
68.5%
91.3%
47.1%
49.2%
50.9%
51.4% 
51.7%
49.7% 
84.0%
91.3% 
82.4%
82.1% 
*Source: Iran national population and housing census, 2006, http://www.sci.org.ir/portal/faces/public/sci_en 
2006 in three provinces of Iran. 
Study population
The general population of three provinces in
Iran were studied. The provinces included 
Golestan, North-East of Iran; Tehran, North-
Center; and Hormozgan, south of Iran. Both urban 
and rural populations were included in Tehran and 
Golestan. In Hormozgan, due to practical
considerations, only the urban population was 
studied. The demography of Iran and the three 
study provinces is given in Table 1. 
In each province, subjects between 18 and 65 
years of age were included. Other inclusion criteria
were Iranian nationality, being a permanent 
inhabitant of the household, and willing to 
participate. 
Sample size calculation
The prevalence of HBsAg positivity in Iran has 
been previously reported to be approximately 3%.7 
Even though hepatitis B vaccination has been
included in the national vaccination program since
1992, this prevalence was used to calculate the 
sample size, because vaccination may not have 
significantly changed the prevalence in adults. 
We calculated our sample size for the detection
of a prevalence of 3% with a confidence level (CI) 
of 95% and error of 0.75% for each province. This 
yielded a sample size of 2000 subjects for each
province. In Tehran, 2500 subjects were selected. 
Sample selection 
Clustered random sampling was used in each 
province. 
We estimated that each research team could
collect data of 20 subjects per day in Hormozgan
and Golestan and 25 subjects in Tehran (due to the 
higher population density).  So, a cluster size of 20
or 25 was chosen respectively which resulted in 
100 clusters in each province to provide the 
calculated sample size.
In Tehran and Hormozgan, we used the list of
postal codes (which are updated annually) for
randomly selecting 100 clusters (families). In 
226 Archives of Iranian Medicine, Volume 12, Number 3, May 2009
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Golestan, family registry of health department, 
which was the most updated population profile,
was used to select clusters. In each cluster, the first
20 (or 25 in Tehran) eligible cases were recruited.
If an eligible subject was not available on the first
visit, a second appointment was scheduled for data 
collection. Subjects were excluded if they refused 
to participate or contact was not possible after two
attempts and they were replaced with the next 
subject in the cluster. 
Data collection 
Data collection was performed during 2006. 
Questionnaires were completed by a trained
interviewer for each subject. The questionnaire 
included demographic and anthropometric data and 
risk factors of HBV infection. The number of 
missing and filled teeth was also recorded as an 
indicator of oral health. 
Laboratory tests
A blood sample was collected from each
participant and then transferred to the regional
laboratory. Serum was separated and stored at
-20°C. Frozen sera were transferred to the Iran 
Blood Transfusion Organization (IBTO) Research 
Center for HBsAg and anti-hepatitis B core 
antibody (anti-HBc) tests. Serum levels of HBsAg 
and anti-HBc were evaluated by Enzygnost HBsAg 
5.0 kit (Dade Behring, Germany) and Hepanostica 
anti-HBc Uni-Form kit (Biomerieux, France), 
respectively.
Statistical analysis 
In each province, to overcome different
response rates, weighted frequencies of HBsAg
and anti-HBc were calculated with weights equal 
to male and female population. For univariate 
analysis, table of frequencies was used to calculate
the prevalence of HBsAg and anti-HBc by 
different potential risk factors. Weighted logistic 
regression was applied to calculate the odds ratio 
and 95%CI for each potential risk factor. Then, 
two different multivariate weighted logistic
regressions were developed to calculate the
independent effects of predictors of HBsAg and 
anti-HBc. In each model, the variables with P<0.2 
in univariate analysis were entered and weights
were equal to population of provinces. Due to high 
missing values of risk factor data in Golestan, 
multivariate analysis was restricted to Tehran and
Hormozgan. Data were analyzed by Stata 10.0 
(StatCorp, College Station, TX). 
Ethics 
The study was approved by the Institutional
Review Board of the Digestive Disease Research
Center of Tehran University of Medical Sciences. 
Written or informed consents were obtained from 
all participants before data collection. 
Results
A total of 6,583 subjects were interviewed in 
the three provinces. After reviewing the data, we 
noticed that the age criterion was not strictly 
observed in Hormozgan and Golestan Provinces 
and 381 subjects were younger than 18 or older
than 65 who were excluded. Five hundred and
twenty-four subjects refused to give blood samples 
or their samples were unsuitable. So, a total of 
5,678 samples were analyzed. Demographic 
characteristics of the study population are shown in 
Table 2. 
The rate of HBsAg and anti-HBc positivity is
given in Table 3. The total prevalence was 
calculated by adjusting for the population of each 
province in addition to sex ratio. 
Data for rural area of Hormozgan was not
available; thus, our reports on rural areas are based
on data from Golestan and Tehran only.
The prevalence of neither HBsAg (P=0.2) nor
anti-HBc (P=0.9) was different according to 
gender. The prevalence of HBsAg and anti-HBc
increased significantly with age (P<0.0001)
[Figures 1a and 1b]. In univariate analysis, HBsAg 
was correlated with history of blood transfusion,
history of traditional phlebotomy (hejamat, 
cupping), history of tattooing, having a family
member with liver diseases, living in rural areas, 
Table 2. Demographic data of the study population. 
 Participants 
 interviewed  Number valid
Samples 
 collected  Percent male  Percent rural
Mean age ± SD 
 (yr)
Tehran 2561 2561 2327  41.6%  5.2% 35.6±13.6
Hormozgan 1987 1745 1455  45.2% 0% 33.4±11.9
Golestan 2035 1896 1896  32.0%  48.2% 38.8±12.9
Total 6583 6202 5678  39.3%  18.6% 36.1±13.1
 
 
 
 
  
 
  
 
 
 
 
   
  
 
 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HBV infection in Iran 
Table 3. Prevalence of anti-HBc and HBsAg in three 
provinces of Iran. 
  Anti-HBc HBs Ag 
 Tehran
Hormozgan 
Golestan 
 Weighted total*
Male 
Female 
Weighted total 
Male 
Female 
Weighted  total 
Male 
Female 
Weighted  total 
Male 
Female 
 Total
 15.4%
 13.0%
 14.2%
 14.8%
 11.7%
 13.3%
 39.8%
 34.0%
 36.9%
 17.7%
 15.0%
 16.4%
 2.7%
 1.8%
 2.3%
 3.4%
 2.0%
 2.7%
 5.4%
 4.8%
 5.1%
 3.0%
 2.1%
 2.6%
* Adjusted for the population of each province. 
 
 
 
 
 
 
 
and less than 12 years of education. Anti-HBc was
correlated with history of surgery, history of
traditional phlebotomy, having a family member 
with liver diseases, living in rural areas, and less
than 12 years of education (Tables 4). But in 
multivariate analysis, only age and having a family 
member with liver disease was correlated with
both HBsAg and anti-HBc. Furthermore, living in
rural area and less than 12 years of education was
associated with HBsAg and anti-HBc in 
multivariate analysis respectively (Table 5). 
Discussion
The sera of 5,678 randomly selected subjects 
were tested in three provinces of Iran for the 
presence of HBsAg and anti-HBc. The rate of 
HBsAg and anti-HBc positivity was 2.6% and 
16.4%, respectively.
Other than being population-based, there are 
some characteristics of our study which should be 
noted. Very few studies in the literature have 
commented on the prevalence of HBV infection in 
rural areas of Iran. We demonstrated that exposure 
rates were higher in rural vs. urban areas of Iran. 
Furthermore, our study population was composed
of more females than males, whereas many
previous studies have reported almost exclusively 
on males. This is especially true for blood donor 
studies where the female population has always
been much smaller since only around 10% of blood
donors are women. Unlike most previous studies, 
we did not find a significantly higher rate of 
HBsAg or anti-HBc in men vs. women. 
Routine vaccination of newborns against HBV
has been implemented in Iran since 1992. We have
studied subjects older than 18 years, so none of our
subjects had received HBV vaccination as part of 
the routine nationwide vaccination program. The
rate of HBsAg positivity is an indicator of the 
prevalence of chronic HBV infection whereas anti-
HBc positivity can be regarded as an indicator of 
past exposure to HBV. Anti-HBc positivity 
underestimates past exposure to HBV since 
subjects who clear the infection may gradually 
loose anti-HBc. 
In Figure 1, it is seen that the prevalence of 
HBsAg and anti-HBc increases with age, 
indicating exposure to HBV in all age groups. 
There is a small peak at age 40 for both HBsAg
and anti-HBc. The significance of this peak is
unknown.
Another important characteristic of our study is
multivariate analysis of risk factors which has 
rarely been performed in earlier reports from Iran.
Risk factors such as tattooing, cupping, and non-
intravenous drug abuse, disappear when
controlling for other variables such as education
and living in rural areas. This might indicate that 
when a good level of education is present,
Figure 1 (a and b). Age specific prevalence of HBsAg and  
anti-HBc in the study population.
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Table 4. Risk factors associated with HBsAg and anti-HBc positivity in Tehran and Hormozgan provinces in univariate
analysis.  
Anti-
HBc
Odds ratio 
(95%CI) P value 
HBs 
Ag 
Odds ratio 
(95% CI) P value 
History of blood transfusion
  Yes
  No
17% 
13% 
1.4(0.9–2.0) 0.1 5% 
2% 
2.2 (1.1–4.4) 0.03
Nonintravenous drug abuse 
  Yes
  No
18% 
13% 
1.5(0.9–2.6) 0.1 1% 
2% 
0.5 (0.1–3.7) 0.5
History of surgery
  Yes
  No
16% 
12% 
1.5(1.2–1.8) 0.001 3% 
2% 
1.4(0.8–2.3) 0.2
History of traditional phlebotomy 
  Yes
  No
18% 
13% 
1.5(1.1–2.0) 0.006 4% 
2% 
2.1(1.1–3.9) 0.02
History of tattooing 
  Yes
  No
18% 
13% 
1.3(0.9–2.0) 0.2 4% 
2% 
2.2(1.0–4.7) 0.04
Family member with liver disease 
  Yes
  No
21% 
13% 
1.8(1.2–2.5) 0.002 6% 
2% 
3.3(1.7–6.2) <0.0001
Rural*
  Yes
  No
39% 
17% 
2.5(1.9–3.1) <0.0001 6% 
3% 
2.7 (1.6–4.5) <0.0001
Less than 12 years education*
  Yes 28% 2.5 (2.1–3.1) <0.0001 4% 1.8 (1.1–3.0) 0.015
  No 12% 3% 
* In all three provinces.
tattooing, cupping, or even drug abuse is not
associated with HBV transmission. 
In the earliest studies on the prevalence of HBV
infection in Iran, the rate of HBsAg positivity
among healthy nonprofessional blood donors was 
3.4%. Our study indicated a rate of 2.6% in the 
general population, i.e. a decrease of 0.8%. 
Interestingly, recent reports from blood donors
show a much greater decrease from almost 3% in 
early studies to 1.79% in 1998 and 0.41% in
2007,18 and in the case of Tehran, 0.51%.19 This 
indicates the effectiveness of the donor selection
procedure being practiced by the IBTO during the 
recent years. In this procedure, donors having 
certain risk factors are excluded from the blood 
donor pool.
We observed a prevalence of 2.6% for HbsAg; 
however, another recent study performed on the
general population reported a very different 
prevalence of 1.7%.8 By reviewing the current 
literature on the prevalence of HBV infection in 
Iran, it is seen that reports from different provinces 
vary widely.20–24 This important phenomenon was 
also well-demonstrated in the present study where
 
 
 
   
   
  
 
 
 
   
   
   
Table 5. Logistic regression of predictors of HBsAg and anti-HBc seropositivity.*
HBsAg positivity 
Odds ratio P value 
Age (for every 10 years)
Having family member with liver disease 
Living in rural area 
(95% CI)
1.3 (1.1–1.6)
3.0(1.6–5.9)
3.0 (1.2–7.2)
0.001
0.001
0.01
Anti-HBc positivity 
Odds ratio P value 
Age (for every 10 years)
Having family member with liver disease 
Less than 12 years education
(95% CI)
1.6 (1.5–1.8)
1.7 (1.1–.4)
1.5 (1.1–1.9)
<0.0001
0.008
0.005
*Area under curve for ROC=0.70 and P value for goodness of fit =0.5. 
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HBV infection in Iran 
the prevalence of HBsAg in Golestan Province was
shown to be almost two times more than those of 
the other two provinces. Iran is a large country
with an area of approximately 1,700,000 square 
kilometers. The people residing in different parts 
of the country have different ethnicities and 
different lifestyles. Golestan is largely populated 
by Torkamans; a tribe which has limited contact
with the rest of the country and rarely marries non-
Torkamans. Torkamans generally follow their
traditional lifestyle. Hormozgan is close to the 
Arab states south of the Persian Gulf and Oman
Sea. Many Iranians living in Hormozgan have 
regular visits to countries like the UAE and Qatar. 
Tehran, the capital, comprises a mixture of various
ethnicities. It is densely populated and western life­
style is dominant. It is not appropriate to compare 
the results of studies performed in different 
provinces of Iran. Furthermore, due to the 
significant improvement in general health during
the recent years and implementation of nationwide
vaccination programs, the prevalence of HBV 
infection is changing rapidly, especially in younger
Iranians. Thus, the age of subjects has an important 
influence on the rates reported by various studies. 
The rates reported by such studies, including ours, 
should be interpreted with caution and careful 
attention to the study population.
Hepatitis B infection is the most common cause 
of chronic liver disease in the world, including 
Iran.1,5 Although vaccination against hepatitis B 
infection is becoming a standard practice, it will be
decades before such vaccination programs actually 
decrease the burden of chronic hepatitis B 
infection. Governments should continue evaluating 
the epidemiology of HBV infection and take
measures for infected individuals.  
According to our results, an estimated two 
million Iranian adults over 18 years of age have 
chronic HBV infection that needs attention. HBV 
infection will remain the major etiology of end- 
stage liver disease for the next 50 years.25,26 More 
than 90% of HBV infections in Iran are e antigen-
negative precore mutants and almost 100% are of 
the D1 genotype.27 There are very few studies on 
the natural history of e antigen-negative genotype 
D1 HBV infection but published studies clearly
show a pattern different from the Asian genotypes
B and C.28 The incidence of HCC is much lower in 
D1 genotype, as is the case in Iran where HCC is
not among the top 10 most common cancers in
Golestan in spite of a 5.5% prevalence of HBsAg
positivity.29 Even the response to treatment is
different and the D1 genotype responds poorly to
interferon.30 Thus, applying guidelines developed 
for Asian genotype B and C to the D1 genotype in
Iran is not appropriate. In order to manage the two
million Iranians infected with HBV, we need a 
guideline based on strong evidence. We should
perform long-term studies on large cohorts of 
HBV-infected Iranians. 
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